Abstract | INTRODUCTION: PATIENTS AND METHODS: RESULTS: Inclusion was discontinued because of high-grade 3 to 5 radiation-pneumonitis events (6 of 19 patients, 31.6%), including one treatment-related death associated with radiation pneumonitis. Median follow-up was 11.9 months. Most common grades 3/4 hematological side effects comprised anemia, neutropenia 3 of 19 patients, each (15.8%), and thrombocytopenia (4 of 19, 21.1%) during induction. Partial response was observed in 10 patients (52.6%) following induction chemotherapy. After concurrent chemo- radiotherapy, overall response was 68.4%. Four patients (21.1%) underwent surgical resection. Median progression-free survival and overall survival were 12 +/- 1 month (95% confidence interval [CI], 9.8-14.1) and 21 +/- 3.5 months (95% CI, 14-27.9 months), respectively. CONCLUSION:
|
Authors | Oscar Arrieta, Dolores Gallardo-Rincón, Cynthia Villarreal-Garza, Rosa M Michel, Alma M Astorga-Ramos, Luis Martínez-Barrera, Jaime de la Garza |
Journal | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
(J Thorac Oncol)
Vol. 4
Issue 7
Pg. 845-52
(Jul 2009)
ISSN: 1556-1380 [Electronic] United States |
PMID | 19487963
(Publication Type: Journal Article)
|
Chemical References |
- Radiation-Sensitizing Agents
- Deoxycytidine
- Carboplatin
- Gemcitabine
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Area Under Curve
- Carboplatin
(administration & dosage, adverse effects)
- Carcinoma, Non-Small-Cell Lung
(drug therapy, pathology, radiotherapy)
- Combined Modality Therapy
- Deoxycytidine
(administration & dosage, adverse effects, analogs & derivatives)
- Disease Progression
- Female
- Humans
- Lung Neoplasms
(drug therapy, pathology, radiotherapy)
- Male
- Mexico
(epidemiology)
- Middle Aged
- Neoplasm Staging
- Radiation Pneumonitis
(epidemiology)
- Radiation-Sensitizing Agents
(administration & dosage, adverse effects)
- Radiotherapy Dosage
- Survival Rate
- Gemcitabine
|